INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24501, 21498, 'Sapropterin', 'Kidney Diseases', 'Patients with renal impairment have not been evaluated in sapropterin clinical trials.  Monitor patients who have renal impairment carefully if receiving treatment with sapropterin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24502, 1892, 'Salmon calcitonin', 'Hypocalcemia', 'Calcitonin inhibits bone resorption, which results in decreased serum calcium levels.  Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption.  Because of the drug''s acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances.  Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects.  Hypocalcemia should preferably be corrected prior to initiation of therapy.  If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24503, 8118, 'Salmon calcitonin', 'Hypocalcemia', 'Calcitonin inhibits bone resorption, which results in decreased serum calcium levels.  Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption.  Because of the drug''s acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances.  Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects.  Hypocalcemia should preferably be corrected prior to initiation of therapy.  If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24504, 14315, 'Salmon calcitonin', 'Hypocalcemia', 'Calcitonin inhibits bone resorption, which results in decreased serum calcium levels.  Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption.  Because of the drug''s acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances.  Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects.  Hypocalcemia should preferably be corrected prior to initiation of therapy.  If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24505, 15426, 'Salmon calcitonin', 'Hypocalcemia', 'Calcitonin inhibits bone resorption, which results in decreased serum calcium levels.  Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption.  Because of the drug''s acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances.  Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects.  Hypocalcemia should preferably be corrected prior to initiation of therapy.  If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24506, 15661, 'Salmon calcitonin', 'Hypocalcemia', 'Calcitonin inhibits bone resorption, which results in decreased serum calcium levels.  Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption.  Because of the drug''s acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances.  Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects.  Hypocalcemia should preferably be corrected prior to initiation of therapy.  If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24507, 19668, 'Salmon calcitonin', 'Hypocalcemia', 'Calcitonin inhibits bone resorption, which results in decreased serum calcium levels.  Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption.  Because of the drug''s acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances.  Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects.  Hypocalcemia should preferably be corrected prior to initiation of therapy.  If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24508, 22687, 'Salmon calcitonin', 'Hypocalcemia', 'Calcitonin inhibits bone resorption, which results in decreased serum calcium levels.  Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption.  Because of the drug''s acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances.  Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects.  Hypocalcemia should preferably be corrected prior to initiation of therapy.  If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24509, 22688, 'Salmon calcitonin', 'Hypocalcemia', 'Calcitonin inhibits bone resorption, which results in decreased serum calcium levels.  Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption.  Because of the drug''s acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances.  Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects.  Hypocalcemia should preferably be corrected prior to initiation of therapy.  If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24510, 22690, 'Salmon calcitonin', 'Hypocalcemia', 'Calcitonin inhibits bone resorption, which results in decreased serum calcium levels.  Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption.  Because of the drug''s acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances.  Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects.  Hypocalcemia should preferably be corrected prior to initiation of therapy.  If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24511, 26484, 'Salmon calcitonin', 'Hypocalcemia', 'Calcitonin inhibits bone resorption, which results in decreased serum calcium levels.  Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption.  Because of the drug''s acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances.  Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects.  Hypocalcemia should preferably be corrected prior to initiation of therapy.  If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24512, 26485, 'Salmon calcitonin', 'Hypocalcemia', 'Calcitonin inhibits bone resorption, which results in decreased serum calcium levels.  Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption.  Because of the drug''s acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances.  Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects.  Hypocalcemia should preferably be corrected prior to initiation of therapy.  If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24513, 30249, 'Salmon calcitonin', 'Hypocalcemia', 'Calcitonin inhibits bone resorption, which results in decreased serum calcium levels.  Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption.  Because of the drug''s acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances.  Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects.  Hypocalcemia should preferably be corrected prior to initiation of therapy.  If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24514, 30250, 'Salmon calcitonin', 'Hypocalcemia', 'Calcitonin inhibits bone resorption, which results in decreased serum calcium levels.  Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption.  Because of the drug''s acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances.  Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects.  Hypocalcemia should preferably be corrected prior to initiation of therapy.  If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24515, 1892, 'Salmon calcitonin', 'Vitamin D Deficiency', 'When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy.  The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body.  In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24516, 8118, 'Salmon calcitonin', 'Vitamin D Deficiency', 'When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy.  The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body.  In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24517, 14315, 'Salmon calcitonin', 'Vitamin D Deficiency', 'When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy.  The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body.  In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24518, 15426, 'Salmon calcitonin', 'Vitamin D Deficiency', 'When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy.  The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body.  In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24519, 15661, 'Salmon calcitonin', 'Vitamin D Deficiency', 'When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy.  The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body.  In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24520, 19668, 'Salmon calcitonin', 'Vitamin D Deficiency', 'When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy.  The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body.  In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24521, 22687, 'Salmon calcitonin', 'Vitamin D Deficiency', 'When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy.  The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body.  In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24522, 22688, 'Salmon calcitonin', 'Vitamin D Deficiency', 'When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy.  The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body.  In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24523, 22690, 'Salmon calcitonin', 'Vitamin D Deficiency', 'When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy.  The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body.  In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24524, 26484, 'Salmon calcitonin', 'Vitamin D Deficiency', 'When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy.  The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body.  In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24525, 26485, 'Salmon calcitonin', 'Vitamin D Deficiency', 'When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy.  The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body.  In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24526, 30249, 'Salmon calcitonin', 'Vitamin D Deficiency', 'When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy.  The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body.  In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24527, 30250, 'Salmon calcitonin', 'Vitamin D Deficiency', 'When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy.  The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body.  In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24528, 0, 'Sargramostim', 'Arrhythmias, Cardiac', 'Transient supraventricular arrhythmia has been reported occasionally during sargramostim administration, particularly in patients with a history of cardiac arrhythmias.  Therapy with sargramostim should be administered cautiously in patients with preexisting cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24529, 0, 'Sargramostim', 'Water-Electrolyte Imbalance', 'Sargramostim may cause fluid retention.  Edema, capillary leak syndrome, and pleural and/or pericardial effusion have been reported.  Therapy with sargramostim should be administered cautiously in patients with preexisting fluid retention or congestive heart failure.  Fluid retention caused or worsened by sargramostim is often reversible following discontinuation of therapy or reduction in dosage, with or without diuretic administration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24530, 0, 'Sargramostim', 'Liver Diseases', 'In patients with preexisting hepatic impairment, the administration of sargramostim may induce elevations of bilirubin and liver enzymes, which are generally reversible following a dosage reduction or therapy interruption.  Monitoring of hepatic function before treatment initiation, and at least every other week during therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24531, 0, 'Sargramostim', 'Leukocytosis', 'Sargramostim is a growth factor for hematopoietic progenitor cells.  Therefore, it should not be used in patients with leukocytosis.  During sargramostim treatment, if the absolute neutrophil count (ANC) exceeds 20,000 cells/mm3 or white blood cell count (WBC) exceeds 50,000 cells/mm3, therapy should be interrupted or the dosage reduced by half, depending on the clinical condition of the patient.  Blood counts generally return to normal or baseline levels within 3 to 7 days of stopping therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24532, 0, 'Sargramostim', 'Leukemia, Myeloid', 'Sargramostim primarily stimulates the proliferation of normal myeloid precursor cells but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with sargramostim should be administered cautiously in patients with myeloid tumors.  Additionally, if sargramostim is used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24533, 0, 'Sargramostim', 'Premature Birth', 'The use of Leukine (brand of sargramostim) liquid or lyophilized powder reconstituted with Bacteriostatic Water for Injection is considered by the drug manufacturer to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  These preparations contain benzyl alcohol which, in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol- free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24534, 0, 'Sargramostim', 'Kidney Diseases', 'In patients with preexisting renal impairment, the administration of sargramostim may induce elevations of serum creatinine, which are generally reversible following a dosage reduction or therapy interruption.  Monitoring of renal function at least every other week during therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24535, 0, 'Sargramostim', 'Lung Diseases', 'Sargramostim may cause an influx of granulocytes in the pulmonary circulation.  Dyspnea has been reported occasionally during or after treatment.  Therapy with sargramostim should be administered cautiously in patients with lung disease or hypoxia.  Respiratory status should be monitored during and immediately after therapy, and the infusion rate reduced by half if dyspnea occurs during IV administration.  In patients who do not respond to the rate reduction or experience a worsening of symptoms, the infusion should be discontinued.  For subsequent infusions, the standard rate schedule may be resumed (with careful monitoring), since respiratory symptoms often do not recur within the same treatment cycle.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24536, 25904, 'Ropinirole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24537, 25905, 'Ropinirole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24538, 25906, 'Ropinirole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24539, 26292, 'Ropinirole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24540, 26293, 'Ropinirole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24541, 26294, 'Ropinirole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24542, 28426, 'Ropinirole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24543, 28427, 'Ropinirole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24544, 25904, 'Ropinirole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24545, 25905, 'Ropinirole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24546, 25906, 'Ropinirole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24547, 26292, 'Ropinirole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24548, 26293, 'Ropinirole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24549, 26294, 'Ropinirole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24550, 28426, 'Ropinirole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24551, 28427, 'Ropinirole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24552, 25904, 'Ropinirole', 'Neuroleptic Malignant Syndrome', 'Neuroleptic malignant syndrome (NMS) has not occurred during administration of ropinirole,  however, the syndrome has rarely been precipitated by rapid dosage reduction, abrupt discontinuation, or changes in other dopamine agonist therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24553, 25905, 'Ropinirole', 'Neuroleptic Malignant Syndrome', 'Neuroleptic malignant syndrome (NMS) has not occurred during administration of ropinirole,  however, the syndrome has rarely been precipitated by rapid dosage reduction, abrupt discontinuation, or changes in other dopamine agonist therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24554, 25906, 'Ropinirole', 'Neuroleptic Malignant Syndrome', 'Neuroleptic malignant syndrome (NMS) has not occurred during administration of ropinirole,  however, the syndrome has rarely been precipitated by rapid dosage reduction, abrupt discontinuation, or changes in other dopamine agonist therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24555, 26292, 'Ropinirole', 'Neuroleptic Malignant Syndrome', 'Neuroleptic malignant syndrome (NMS) has not occurred during administration of ropinirole,  however, the syndrome has rarely been precipitated by rapid dosage reduction, abrupt discontinuation, or changes in other dopamine agonist therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24556, 26293, 'Ropinirole', 'Neuroleptic Malignant Syndrome', 'Neuroleptic malignant syndrome (NMS) has not occurred during administration of ropinirole,  however, the syndrome has rarely been precipitated by rapid dosage reduction, abrupt discontinuation, or changes in other dopamine agonist therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24557, 26294, 'Ropinirole', 'Neuroleptic Malignant Syndrome', 'Neuroleptic malignant syndrome (NMS) has not occurred during administration of ropinirole,  however, the syndrome has rarely been precipitated by rapid dosage reduction, abrupt discontinuation, or changes in other dopamine agonist therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24558, 28426, 'Ropinirole', 'Neuroleptic Malignant Syndrome', 'Neuroleptic malignant syndrome (NMS) has not occurred during administration of ropinirole,  however, the syndrome has rarely been precipitated by rapid dosage reduction, abrupt discontinuation, or changes in other dopamine agonist therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24559, 28427, 'Ropinirole', 'Neuroleptic Malignant Syndrome', 'Neuroleptic malignant syndrome (NMS) has not occurred during administration of ropinirole,  however, the syndrome has rarely been precipitated by rapid dosage reduction, abrupt discontinuation, or changes in other dopamine agonist therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24560, 25904, 'Ropinirole', 'Cardiovascular Diseases', 'The trials of ropinirole excluded patients with significant cardiovascular disease, hence patients with cardiovascular conditions should be treated with caution.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24561, 25905, 'Ropinirole', 'Cardiovascular Diseases', 'The trials of ropinirole excluded patients with significant cardiovascular disease, hence patients with cardiovascular conditions should be treated with caution.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24562, 25906, 'Ropinirole', 'Cardiovascular Diseases', 'The trials of ropinirole excluded patients with significant cardiovascular disease, hence patients with cardiovascular conditions should be treated with caution.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24563, 26292, 'Ropinirole', 'Cardiovascular Diseases', 'The trials of ropinirole excluded patients with significant cardiovascular disease, hence patients with cardiovascular conditions should be treated with caution.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24564, 26293, 'Ropinirole', 'Cardiovascular Diseases', 'The trials of ropinirole excluded patients with significant cardiovascular disease, hence patients with cardiovascular conditions should be treated with caution.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24565, 26294, 'Ropinirole', 'Cardiovascular Diseases', 'The trials of ropinirole excluded patients with significant cardiovascular disease, hence patients with cardiovascular conditions should be treated with caution.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24566, 28426, 'Ropinirole', 'Cardiovascular Diseases', 'The trials of ropinirole excluded patients with significant cardiovascular disease, hence patients with cardiovascular conditions should be treated with caution.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24567, 28427, 'Ropinirole', 'Cardiovascular Diseases', 'The trials of ropinirole excluded patients with significant cardiovascular disease, hence patients with cardiovascular conditions should be treated with caution.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24568, 25904, 'Ropinirole', 'Liver Diseases', 'The pharmacokinetic disposition of ropinirole has not been studied in patients with hepatic impairment, however, the serum concentration of ropinirole may be increased and the elimination half-life prolonged in these patients.  Therapy with ropinirole should be administered cautiously in patients with hepatic impairment, and dosages titrated according to patient parameters and clinical tolerability.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24569, 25905, 'Ropinirole', 'Liver Diseases', 'The pharmacokinetic disposition of ropinirole has not been studied in patients with hepatic impairment, however, the serum concentration of ropinirole may be increased and the elimination half-life prolonged in these patients.  Therapy with ropinirole should be administered cautiously in patients with hepatic impairment, and dosages titrated according to patient parameters and clinical tolerability.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24570, 25906, 'Ropinirole', 'Liver Diseases', 'The pharmacokinetic disposition of ropinirole has not been studied in patients with hepatic impairment, however, the serum concentration of ropinirole may be increased and the elimination half-life prolonged in these patients.  Therapy with ropinirole should be administered cautiously in patients with hepatic impairment, and dosages titrated according to patient parameters and clinical tolerability.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24571, 26292, 'Ropinirole', 'Liver Diseases', 'The pharmacokinetic disposition of ropinirole has not been studied in patients with hepatic impairment, however, the serum concentration of ropinirole may be increased and the elimination half-life prolonged in these patients.  Therapy with ropinirole should be administered cautiously in patients with hepatic impairment, and dosages titrated according to patient parameters and clinical tolerability.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24572, 26293, 'Ropinirole', 'Liver Diseases', 'The pharmacokinetic disposition of ropinirole has not been studied in patients with hepatic impairment, however, the serum concentration of ropinirole may be increased and the elimination half-life prolonged in these patients.  Therapy with ropinirole should be administered cautiously in patients with hepatic impairment, and dosages titrated according to patient parameters and clinical tolerability.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24573, 26294, 'Ropinirole', 'Liver Diseases', 'The pharmacokinetic disposition of ropinirole has not been studied in patients with hepatic impairment, however, the serum concentration of ropinirole may be increased and the elimination half-life prolonged in these patients.  Therapy with ropinirole should be administered cautiously in patients with hepatic impairment, and dosages titrated according to patient parameters and clinical tolerability.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24574, 28426, 'Ropinirole', 'Liver Diseases', 'The pharmacokinetic disposition of ropinirole has not been studied in patients with hepatic impairment, however, the serum concentration of ropinirole may be increased and the elimination half-life prolonged in these patients.  Therapy with ropinirole should be administered cautiously in patients with hepatic impairment, and dosages titrated according to patient parameters and clinical tolerability.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24575, 28427, 'Ropinirole', 'Liver Diseases', 'The pharmacokinetic disposition of ropinirole has not been studied in patients with hepatic impairment, however, the serum concentration of ropinirole may be increased and the elimination half-life prolonged in these patients.  Therapy with ropinirole should be administered cautiously in patients with hepatic impairment, and dosages titrated according to patient parameters and clinical tolerability.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24576, 25904, 'Ropinirole', 'Kidney Diseases', 'Ropinirole is primarily eliminated by the kidney.  Less than 10% of ropinirole is excreted unchanged in the urine.  No dose adjustment is necessary in patients with moderate renal impairment (CrCl 30 to 50 mL/min).  For patients with end-stage renal disease on hemodialysis, a reduced maximum dose is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24577, 25905, 'Ropinirole', 'Kidney Diseases', 'Ropinirole is primarily eliminated by the kidney.  Less than 10% of ropinirole is excreted unchanged in the urine.  No dose adjustment is necessary in patients with moderate renal impairment (CrCl 30 to 50 mL/min).  For patients with end-stage renal disease on hemodialysis, a reduced maximum dose is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24578, 25906, 'Ropinirole', 'Kidney Diseases', 'Ropinirole is primarily eliminated by the kidney.  Less than 10% of ropinirole is excreted unchanged in the urine.  No dose adjustment is necessary in patients with moderate renal impairment (CrCl 30 to 50 mL/min).  For patients with end-stage renal disease on hemodialysis, a reduced maximum dose is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24579, 26292, 'Ropinirole', 'Kidney Diseases', 'Ropinirole is primarily eliminated by the kidney.  Less than 10% of ropinirole is excreted unchanged in the urine.  No dose adjustment is necessary in patients with moderate renal impairment (CrCl 30 to 50 mL/min).  For patients with end-stage renal disease on hemodialysis, a reduced maximum dose is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24580, 26293, 'Ropinirole', 'Kidney Diseases', 'Ropinirole is primarily eliminated by the kidney.  Less than 10% of ropinirole is excreted unchanged in the urine.  No dose adjustment is necessary in patients with moderate renal impairment (CrCl 30 to 50 mL/min).  For patients with end-stage renal disease on hemodialysis, a reduced maximum dose is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24581, 26294, 'Ropinirole', 'Kidney Diseases', 'Ropinirole is primarily eliminated by the kidney.  Less than 10% of ropinirole is excreted unchanged in the urine.  No dose adjustment is necessary in patients with moderate renal impairment (CrCl 30 to 50 mL/min).  For patients with end-stage renal disease on hemodialysis, a reduced maximum dose is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24582, 28426, 'Ropinirole', 'Kidney Diseases', 'Ropinirole is primarily eliminated by the kidney.  Less than 10% of ropinirole is excreted unchanged in the urine.  No dose adjustment is necessary in patients with moderate renal impairment (CrCl 30 to 50 mL/min).  For patients with end-stage renal disease on hemodialysis, a reduced maximum dose is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24583, 28427, 'Ropinirole', 'Kidney Diseases', 'Ropinirole is primarily eliminated by the kidney.  Less than 10% of ropinirole is excreted unchanged in the urine.  No dose adjustment is necessary in patients with moderate renal impairment (CrCl 30 to 50 mL/min).  For patients with end-stage renal disease on hemodialysis, a reduced maximum dose is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24584, 8103, 'Salmeterol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24585, 8103, 'Salmeterol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24586, 8103, 'Salmeterol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24587, 8103, 'Salmeterol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24588, 8103, 'Salmeterol', 'Liver Diseases', 'Salmeterol is predominantly cleared by hepatic metabolism and liver dysfunction might lead to accumulation of salmeterol in plasma.  Patients with hepatic disease should be closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24589, 0, 'Sarilumab', 'Infections', 'Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in rheumatoid arthritis patients receiving sarilumab; the most common serious infections reported included pneumonia and cellulitis.  Use of sarilumab should be avoided in patients with an active infection, including localized infections.  The risks and benefits of treatment should be considered before starting sarilumab in patients:  with chronic/recurrent infection, who have been exposed to tuberculosis, with history of serious/opportunistic infection, who have resided/traveled in areas of endemic tuberculosis/mycoses, or with underlying conditions that may predispose them to infection.  Patients should be closely monitored for signs/symptoms of infection during sarilumab treatment as signs/symptoms of acute inflammation may be reduced due to suppression of acute phase reactants.  If a serious infection or an opportunistic infection develops, sarilumab should be interrupted until the infection is controlled.  A patient who develops a new infection during treatment with sarilumab should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be started, and the patient should be monitored closely.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24590, 0, 'Sarilumab', 'Tuberculosis', 'Sarilumab should not be given to patients with active tuberculosis (TB) infection.  Patients should be evaluated for TB risk factors and tested for latent infection before starting sarilumab and during therapy; if positive for latent TB, patients should be treated with standard antimycobacterial therapy before starting sarilumab.  Anti-TB therapy should be considered prior to starting sarilumab in patients with history of latent/active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but having risk factors for TB infection.  Consultation with a physician with expertise in TB may be appropriate when considering anti-TB therapy.  Patients should be closely monitored for signs/symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24591, 0, 'Sarilumab', 'Hematologic Diseases', 'The use of sarilumab is associate with higher incidence of decrease in absolute neutrophil count (ANC), including neutropenia and thrombocytopenia.  It is recommended to assess neutrophil count and platelet count prior to initiation of therapy and monitor these levels 4 to 8 weeks after start of therapy and every 3 months thereafter.  Dose modification may be necessary based on the pharmacodynamics of the changes in ANC.  Care is recommended when using this agent in patients with blood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24592, 0, 'Sarilumab', 'Diverticulitis', 'Gastrointestinal (GI) perforations have been reported with the use of sarilumab.  GI perforation risk may be increased with concurrent diverticulitis or concomitant use of NSAIDs or corticosteroids.  Assess patients for gastrointestinal complications prior to beginning therapy and promptly evaluate patients presenting with new onset abdominal symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24593, 0, 'Sarilumab', 'Hepatic Insufficiency', 'The use of sarilumab is associate with transaminase elevations; therefore, treatment with sarilumab is not recommended in patients with active hepatic disease or hepatic impairment.  It is recommended to assess ALT/AST levels prior to initiation of treatment and monitor ALT and AST levels 4 to 8 weeks after start of therapy and every 3 months thereafter.  When clinically indicated, consider other liver function tests such as bilirubin.  Dose modification based on transaminase elevations might be warranted.  The safety and efficacy or sarilumab have not been conducted in patients with hepatic impairment, including patients with positive HBV or HCV serology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24594, 0, 'Sarilumab', 'Hyperlipidemias', 'The use of sarilumab is associate with increases in lipid parameters such as LDL cholesterol, HDL cholesterol and/or triglycerides.  Care should be exercised when using this agent in patients with lipid abnormalities.  It is recommended to assess lipid parameters at baseline and parameters approximately 4 to 8 weeks following initiation of treatment, then at approximately 6 months intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24595, 0, 'Sarilumab', 'Kidney Diseases', 'Monoclonal antibodies, including sarilumab, are not eliminated via renal pathway.  No dose adjustment is required in patients with mild to moderate renal impairment.  The use of sarilumab has not been evaluated in patients with severe renal impairment.  Care should be exercised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24596, 0, 'Saquinavir', 'Hemophilia A', 'There have been postmarketing reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in types A and B hemophiliac patients treated with protease inhibitors.  However, a causal relationship has not been established.  In some patients, additional Factor VIII was given.  In more than half of the reported cases, protease inhibitor therapy was continued or reintroduced following an interruption.  Hemophiliacs and patients with other coagulation defects should be monitored closely for bleeding during protease inhibitor therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24597, 0, 'Saquinavir', 'Long QT Syndrome', 'QT and PR interval dose-dependent prolongation and torsades de pointes have been reported with the use of saquinavir (saquinavir should always be used in combination with ritonavir).  Saquinavir should not be used in patients with congenital long QT syndrome, patients with refractory hypokalemia or hypomagnesemia, or in combination with other drugs that can both prolong the QT interval and increase the plasma concentration of saquinavir.  Saquinavir is also contraindicated in patients with a complete atrioventricular (AV) block without an implanted pacemaker or patients at risk of a complete AV block.Caution and close EKG and electrolyte monitoring is recommended if therapy is initiated in patients with congestive heart failure, bradyarrhythmias, structural heart disease, cardiomyopathies, ischemic heart disease, hepatic impairment, and electrolyte abnormalities.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24598, 0, 'Saquinavir', 'Hyperglycemia', 'New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, glucose intolerance, hyperglycemia, and some cases of diabetic ketoacidosis have been reported during postmarketing surveillance in HIV-infected patients treated with protease inhibitors (PIs).  In some cases, glucose abnormalities/hyperglycemia persisted despite discontinuation of PI therapy.  Frequently, insulin resistance may accompany fat redistribution and serum lipid elevations in what is collectively termed the HIV-associated lipodystrophy syndrome.  Although a causal relationship has not been established, these metabolic disturbances have most often occurred in HIV-infected patients during treatment with potent antiretroviral regimens containing PIs.  Monitoring patients for hyperglycemia, new onset diabetes mellitus, or exacerbation of diabetes mellitus should be considered during PI therapy.  Dosage adjustments in insulin or oral hypoglycemic medications may be necessary in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24599, 0, 'Saquinavir', 'Hyperlipidemias', 'Hyperlipidemia has been observed in 10% of patients receiving ritonavir during clinical trials.  Increases of 30% to 40% from baseline have been reported for total cholesterol and 200% to 300% or more for triglycerides.  These effects have also been reported during postmarketing experience with other protease inhibitors (PIs) but may be the most dramatic with ritonavir.  The clinical significance of these elevations is unclear.  Severe hyperlipidemia is known to sometimes cause pancreatitis.  In addition, some patients have reportedly developed symptomatic atherosclerosis and coronary artery disease after initiating PI treatment.  Patients with preexisting hyperlipidemia may require closer monitoring during PI therapy, and adjustments made accordingly in their lipid-lowering regimen.  PI therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24600, 0, 'Saquinavir', 'Liver Diseases', 'Saquinavir is primarily metabolized by the liver.  Patients with liver disease may be at greater risk for adverse effects from saquinavir due to decreased drug clearance, so therapy should be administered cautiously in these patients.  Additionally, there have been reports of worsening liver disease in patients with underlying hepatitis B or C, cirrhosis, chronic alcoholism, and other liver abnormalities.  Close monitoring is recommended.  The use of saquinavir when administered with ritonavir is contraindicated in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
